Filing Details
- Accession Number:
- 0001415889-14-001758
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-04 17:05:31
- Reporting Period:
- 2014-06-02
- Filing Date:
- 2014-06-04
- Accepted Time:
- 2014-06-04 17:05:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1016364 | D Ph J Lester Kaplan | 11085 Torreyana Road #100 San Diego CA 92121 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-06-02 | 4,450 | $6.10 | 12,950 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-06-02 | 4,450 | $20.52 | 8,500 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2014-06-02 | 4,450 | $0.00 | 4,450 | $6.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2014-06-13 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2013.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.22 to $20.6625 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following March 12, 2004.
Billionaire Hedge Funds
